— Amgen shares fell 3.7% after the approval of Bristol-Myer Squibb's psoriasis drug, which will compete with Amgen's Otezla.
Separately, the biotech company reported over the weekend that its Lumakras pill reduced the risk of lung cancer progression by 34% compared with chemotherapy in a clinical trial,
Portugal Últimas Notícias, Portugal Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Stocks Making the Biggest Moves Premarket: Carvana, Bristol-Myers Squibb, Alphatec and MoreThese are the stocks posting the largest moves in premarket trading.
Consulte Mais informação »
Twitter whistleblower testimony, consumer price index, Oracle earnings top week aheadFOX Business takes a look at the upcoming events that are likely to move financial markets in the coming days, including some big matters for Twitter. “Every statue and street building has been renamed, every date has been altered. And the process is continuing day by day and minute by minute. History has stopped. Nothing exists except an endless present in which the Party is always right.” - George Orwell, 1984
Consulte Mais informação »